Immunological and Autoimmune Disorders

AstraZeneca announces availability of Saxa / Dapa FDC in UK UK-based AstraZeneca has announced the availability of Qtern for adult patients with type 2 diabetes in the country. Quern is a fixed dose combination of saxagliptin and dapagliflozin. The tablet received marketing authorization from the European Commission on 19 July last year and is indicated in adults aged 18 and older with type 2 diabetes in order to improve glycemic control. The European Commission approved the tablet based on data from three Phase III randomised. Saxa / dapa FDC can be used in patients with mild renal impairment and should be avoided in patients with moderate-to-severe renal impairment. ...